<p>The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. This supplement data from the Beat AML program provides Adolescent and Young Adult (AYA) and pediatric tumor specimens not previously released. These data include exome and RNA level characterization as well as analyses of <i>ex vivo</i> drug sensitivity. Collectively, this data can be leveraged to address clinical, genomic, transcriptomic and functional analyses of the biology of leukemia in pediatric and AYA populations.</p>

NCI CCSG CCDI Supplement Additional Genomic Submission

Leukemia, Myeloid, Acute study with RNA-Seq, Targeted-Capture + 1 more data on dbGaP (104 participants)